NBSE
NeuBase Therapeutics, Inc. [NBSE] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NBSE Stock Summary
In the News
NBSE Financial details
Company Rating
-
Market Cap
1.65M
Income
-14.31M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
37
Optionable
No
Shortable
Yes
Earnings
12 Apr 2024
P/E
-0.14
Forward P/E
-
PEG
0.02
P/S
-
P/B
0.22
P/C
-
P/FCF
-0.18
Quick Ratio
2.7
Current Ratio
2.87
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-8.14
EPS next Y
-
EPS next Q
-
EPS this Y
12.13%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-67.65%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-77%
ROE
-108%
ROC
-1.09%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.39-5.4
52W High
-
52W Low
-
RSI
-
Rel Volume
0.37
Avg Volume
240.2K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
0.959
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
Company Profile
- Volume Average 240.2K
- Market Capitalization 1.65M
- Employee 37
- CEO Dr. Dietrich A. Stephan Ph.D.
- Headquarters Pittsburgh,PA,US
- IPO Date 2004-05-28
-
Website
https://www.neubasetherapeutics.com 
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
